Medpace is a full-service clinical research organization (CRO) that designs and runs clinical trials for biopharmaceutical and medical-device sponsors. It provides end-to-end development support including clinical monitoring, data management, regulatory and medical expertise. The company is known for a scientifically driven model and mid-sized biotech-oriented client base rather than pure volume commodity CRO work.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 603.3 | — | 90.3 | 5.5% |
| Q3 2025 | 659.9 | — | 111.1 | 19.1% |
| Q4 2025 | 708.5 | — | 135.1 | 18.1% |
| Q1 2026 | 706.6 | — | 123.9 | 10.8% |
| Q2 2026 | 707.3 | 17.2% | 121.4 | 34.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: News Corporation (NWSA), Lattice Semiconductor Corporation (LSCC), Jazz Pharmaceuticals plc (JAZZ), Millicom International Cellular S.A. (TIGO), Neurocrine Biosciences, Inc. (NBIX), Akamai Technologies, Inc. (AKAM)